New hope for kids with severe psoriasis: drug trial shows promise

NCT ID NCT03997786

Ongoing Disease control Sponsor: Sun Pharmaceutical Industries Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called tildrakizumab in children aged 6 to 17 with moderate-to-severe plaque psoriasis. The goal is to see if it safely reduces skin symptoms like redness and scaling. Participants receive the drug or a placebo, and researchers monitor results over time. Since psoriasis is a chronic condition, treatment is meant to control it long-term, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Contacts and locations

Locations

Site 1

Fountain Valley, California, 92708, United States
Site 14

Spokane, Washington, 99202, United States
Site 2

Thousand Oaks, California, 91320, United States
Site 20

Miami, Florida, 33126, United States
Site 39

Wroclaw, 51-503, Poland
Site 41

Barcelona, 08041, Spain
Site 47

Las Palmas de Gran Canaria, 35019, Spain
Site 50

Ostrowiec Świętokrzyski, 27-400, Poland
Site 51

Katowice, 40-611, Poland
Site 52

Szczecin, 70-332, Poland
Site 53

Warsaw, 02-507, Poland
Site 54

Lodz, 90-265, Poland
Site 56

Lodz, 90-436, Poland
Site 57

Bialystok, 15-453, Poland
Site 58

Lublin, 20-573, Poland
Site 59

Sosnowiec, 41-200, Poland
Site 61

Debrecen, H-4032, Hungary
Site 62

Budapest, H-1036, Hungary
Site 63

Budapest, H-1033, Hungary
Site 64

Kaposvár, H-7400, Hungary
Site 7

Miami, Florida, 33173, United States
Site 71

Lucknow, 226005, India
Site 74

Surat, 395002, India
Site 79

Ahmedabad, 380009, India
Site 90

Trnava, 91775, Slovakia
Site 91

Svidník, 8901, Slovakia
Site 92

Bardejov, 8501, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.